Beijing Chunlizhengda Medical Instruments (HKG:1858, SHA:688236) expects an attributable profit of between around 107.8 million yuan and 127.8 million yuan for the year 2024, down 54% to 61% from 277.8 million yuan, a year prior, a Friday bourse filing said.
The orthopedic medical device company attributed the lower anticipated profit mainly to a decline in revenue and net profit amid the continuous deepening of its centralized procurement policy leading to lower product prices and adjustments to the price of channel inventory.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.